LeMaitre Vascular/$LMAT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LeMaitre Vascular
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
- Ticker
- $LMAT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 651
- Headquarters
- Burlington, United States
- Website
- www.lemaitre.com
LMAT Metrics
BasicAdvanced
$1.9B
28.31
$2.86
0.52
$0.95
1.24%
Price and volume
Market cap
$1.9B
Beta
0.52
52-week high
$118.01
52-week low
$78.22
Average daily volume
264K
Dividend rate
$0.95
Financial strength
Current ratio
16.312
Quick ratio
13.761
Long term debt to equity
0.444
Total debt to equity
0.453
Dividend payout ratio (TTM)
31.21%
Interest coverage (TTM)
13.95%
Profitability
EBITDA (TTM)
83.021
Gross margin (TTM)
71.87%
Net profit margin (TTM)
25.02%
Operating margin (TTM)
27.63%
Effective tax rate (TTM)
22.50%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
7.44%
Return on equity (TTM)
16.77%
Valuation
Price to earnings (TTM)
28.312
Price to revenue (TTM)
7.019
Price to book
4.4
Price to tangible book (TTM)
5.71
Price to free cash flow (TTM)
24.95
Free cash flow yield (TTM)
4.01%
Free cash flow per share (TTM)
3.244
Dividend yield (TTM)
1.17%
Forward dividend yield
1.24%
Growth
Revenue change (TTM)
11.85%
Earnings per share change (TTM)
39.46%
3-year revenue growth (CAGR)
13.99%
10-year revenue growth (CAGR)
12.37%
3-year earnings per share growth (CAGR)
36.25%
10-year earnings per share growth (CAGR)
19.08%
3-year dividend per share growth (CAGR)
19.30%
10-year dividend per share growth (CAGR)
18.14%
What the Analysts think about LMAT
Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.
Analyst projections of the future price of LeMaitre Vascular stock.
Bulls say / Bears say
Second-quarter revenue grew 10% and EPS rose 23%, while gross margin expanded 210 basis points to 72.1%. That points to pricing, product mix and cost discipline converting growth into profit. (LeMaitre Vascular)
Artegraft sales rose 34% and reached 21% of sales, with approvals in 56 countries; management expects 2026 sales of $11 million, up from $4 million in 2025. Its international rollout offers a clear growth driver. (The Motley Fool)
LeMaitre held $376.2 million in cash and securities, and management described its acquisition pipeline as active while adding a fourth business-development team member. This gives it financial capacity to pursue complementary products, though deals are not assured. (The Motley Fool)
Management cut its 2026 organic growth outlook from 12% to 11% after a quarterly sales shortfall, citing the stronger dollar, delayed Middle East exports and constrained cardiac allograft supply. Those headwinds were expected to continue weighing on the second half. (The Motley Fool)
A June FDA follow-up audit at the New Jersey facility produced additional quality-system observations after a 2025 warning letter. Production and shipments had not been disrupted, but continued regulatory scrutiny could create compliance or supply risk. (The Motley Fool)
President David Roberts plans to retire from his role at year-end, creating a leadership handover as the company works through growth and operational challenges. He intends to remain on the board. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
LMAT Financial Performance
Revenues and expenses
LMAT Earnings Performance
Company profitability
Upcoming events
No upcoming events
LMAT News
AllArticlesVideos
Funds containing LMAT
Fund name | Fund size | $LMAT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.10% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.